Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Denmark
/
Pharmaceuticals & Biotech
Create a narrative
H. Lundbeck Community
CPSE:HLUN B Community
3
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Create a narrative
H. Lundbeck
Popular
Undervalued
Overvalued
Community Investing Ideas
H. Lundbeck
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
Vyepti's Expansion And anti-PACAP Developments Will Strengthen Future Outlook
Key Takeaways Focus on late-stage developments and new product launches, including Vyepti, could drive future revenue growth and global expansion. Strategic capital allocation and acquisition of high-potential assets enhance long-term earnings and support R&D projects.
View narrative
DKK 47.38
FV
25.9% undervalued
intrinsic discount
4.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
4 days ago
author updated this narrative
H. Lundbeck
AN
AnalystLowTarget
Consensus Narrative from 12 Analysts
Patent Cliffs Will Squeeze Margins While Cautious Recovery Materializes
Key Takeaways Heavy reliance on a narrow product portfolio exposes Lundbeck to vulnerabilities from patent expirations and generic competition, potentially limiting long-term growth. Expansion into neuro-rare therapies and international markets faces challenges from high R&D costs, regulatory hurdles, and limited emerging market penetration.
View narrative
DKK 38.00
FV
7.6% undervalued
intrinsic discount
2.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
H. Lundbeck
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Rising Mental Health Awareness Will Expand CNS Treatment Opportunities
Key Takeaways Accelerating adoption of key products, premium pipeline assets, and global demand trends are set to drive sustained revenue growth and margin expansion beyond current expectations. Advanced R&D strategies and CNS biologics leadership position the company for resilient, high-margin growth and competitive differentiation in neurology markets.
View narrative
DKK 64.79
FV
45.8% undervalued
intrinsic discount
6.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
HLUN B
HLUN B
H. Lundbeck
Your Fair Value
DKK
Current Price
DKK 35.10
17.6% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-5b
25b
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 25.4b
Earnings DKK 3.6b
Advanced
Set Fair Value